THTX Theratechnologies Accounting Capitalization

Public company logo of Theratechnologies (THTX)

Theratechnologies Inc. (THTX) is optimizing costs by leveraging Canadian R&D centers and outsourcing drug manufacturing in Europe and the US. The company is currently reducing its dependence on the HIV segment by developing its oncology pipeline and expanding into the EU. The available price action vector, where the metric is fixed at -0.03, complements data on revenues from peptide medicine and endocrine disorder therapies.

THTX Theratechnologies, Inc Book Capitalization (07/04/2022 - 10/11/2025)

Metric breakdowns and analytics for Theratechnologies (THTX)

- price and consensus price forecast:
Price Theratechnologies, Inc|THTX - Consensus Target
- market capitalization data:
Market Capitalization Theratechnologies, Inc.|THTX - Total Company Value
- book capitalization data:
Share Book Value Theratechnologies|THTX - Book Capitalization|Market Value to Book Value theratech.com|THTX - Company Total Assets
- debt and liquidity data:
Total Debt to Capital Theratechnologies Inc.|THTX - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital Theratechnologies, Inc.|THTX - Company Debts|Debt to Book Value Theratechnologies, Inc.|THTX - Company Long-Term Debts|Company Short-Term Debts Theratechnologies
Fundamental valuation:THTX - Theratechnologies, Inc
Flagship merchandise of Theratechnologies, Inc.

The complex pharmaceutical logistics of Theratechnologies Inc. (THTX) require significant capital expenditures in cold storage infrastructure. Balance sheet capitalization reflects the actual value of net assets minus all liabilities. This metric determines the issuer's financial stability during periods of expensive borrowed capital. Analyzing this indicator allows for an assessment of the risk of frozen resources. The trend in balance sheet capitalization visualizes the company's actual margin of safety.

Competitor analysis for Theratechnologies Inc.

argenx BVBA (ARGX) - Total Net Assets|Company Net Assets BioNTech SE|ABVX (ABIVAX) - Accounting Capitalization|Company Book Value ADMA Biologics, Inc. ADMA|Net Asset Value Protagonist Therapeutics, Inc.|Immunovant Corp (IMVT) - Book Capitalization|Accounting Value of Company Kiniksa Corp (KNSA)|Book Capitalization GRFS (Grifols, S.A.)|adaptivebiotech.com - Book Capitalization|Company Book Value Celldex Therapeutics, Inc. (CLDX)|AUPH: Accounting Value of Company|BCRX (BioCryst Pharmaceuticals Inc) - Company Book Value|Vera Corp (VERA) - Company Net Assets|DNTH (Dianthus Therapeutics) - Book Capitalization|Book Capitalization pharvaris.com (PHVS)|AbCellera Bio (ABCL) - Company Net Assets|Accounting Value of Company Tourmaline Bio Inc (TRML)|Book Capitalization PGEN|Pharming Corp - Book Valuation of Business|NKTR: Company Book Value|UPB: Company Net Assets|ZBIO (Zenas Biopharma) - Company Book Value|Company Net Assets Immunome Inc|GOSS (Gossamer Corp) - Company Net Assets|Book Capitalization KALV|Company Book Value Septerna Inc SEPN|Accounting Capitalization pieris.com (PVLA)|SVRA: Book Capitalization|RIGL - Total Stockholders' Equity|Company Net Assets AnaptysBio Corp ANAB|ATXS - Total Net Assets|Book Capitalization enGene Holdings Inc. ENGN|rapt.com (RAPT) - Accounting Value of Company|Book Capitalization JBIO (Aerovate Therapeutics, Inc.)|Total Stockholders' Equity ACRS|Kyverna (KYTX) - Company Book Value|Accounting Value of Company Tiziana Life Sciences, Ltd. (TLSA)|Book Capitalization CABA (Cabaletta Bio, Inc.)|VTYX - Book Capitalization|Company Net Assets Avalo Therapeutics AVTX|ELDN - Total Net Assets|Book Capitalization AGEN|Climb Bio, Inc (CLYM) - Total Stockholders' Equity|Book Capitalization ZURA|Company Net Assets atyrpharma.com|Adagene (ADAG) - Book Capitalization|Accounting Value of Company IMA (ikenaoncology.com)|STTK - Company Book Value|Equillium Inc - Accounting Capitalization|CNTB (Connect Pharma) - Company Book Value|IMUX: Total Stockholders' Equity|atarabio.com (ATRA) - Company Book Value|IFRX (InflaRx) - Company Book Value|Company Book Value XFOR (X4 Pharma)|Total Stockholders' Equity Adicet|CELU: Book Capitalization|Book Value of Business inmunebio.com (INMB)|Book Capitalization BRNS|Book Valuation of Business Kezar Life Sciences Inc. KZR|SABS (SAB Biotherapeutics, Inc) - Book Capitalization|AKTX: Total Stockholders' Equity|enlivex.com - Company Book Value|Book Valuation of Business Q32 Bio|GOVX - Company Net Assets|Accounting Value of Company Edesa Biotech Inc|IBIO (iBio Corp) - Book Capitalization|Book Valuation of Business CARM (carismatx.com)|XTLB - Company Book Value|Accounting Capitalization Bolt Biotherapeutics Inc. BOLT|HCWB: Book Capitalization|Aptevo Therapeutics (APVO) - Company Net Assets|AIM ImmunoTech - Company Net Assets|Book Valuation of Business Aditxt, Inc.|GRI Bio, Inc. (GRI) - Company Net Assets|Total Net Assets xortx.com|Vyome Holdings (HIND) - Book Capitalization|Accounting Value of Company Revelation Biosciences Inc REVB|Company Net Assets Indaptus (INDP)|SCNI - Total Net Assets|CalciMedica Corp (CALI) - Company Net Assets|AFMD: Accounting Capitalization|Company Book Value allakos.com (ALLK)|HOOKIPA Pharma (HOOK) - Net Asset Value|IGMS - Book Capitalization|Accounting Value of Company iTeos Pharma|Book Capitalization OCEA|Book Capitalization TCBP (tcbiopharm.com)|Company Book Value Third Harmonic Bio, Inc.